Acneiform Eruption Secondary to Cetuximab With Pseudomalignant Histopathological Changes

[Acneiform eruption secondary to cetuximab with pseudomalignant histopathological changes].

Actas Dermosifiliogr. 2008;99:157-69 159 subcutaneous tissue simulating celullitis. N Engl J Med. 1950:242: 779-81. 5.Ruiz de Erenchun FR, Vázquez Doval J, Valérdiz S, Serna MJ, Quintanilla E. Inflammatory metastatic carcinoma: a clinical and histopathologic study of three cases. J Dermatol Surg Oncol. 1991; 17:784-7. 6.Tan BB, Marsden JR, Sanders DSA. Melanoma erysipeloides: inflammatory metas...

Acneiform eruption induced by cetuximab.

Cetuximab is a recombinant human/mouse chimeric monoclonal antibody that targets the extracellular domain of the epidermal growth factor receptor (EGFR). Cetuximab is approved by the US Food and Drug Administration for the treatment of EGFR-expressing metastatic colorectal cancer as monotherapy in patients who are intolerant to irinotecan-based chemotherapy, or in combination with irinotecan in...

Severe Acneiform Eruption Induced by Cetuximab (Erbitux®)

Epidermal growth factor has an important role in the regulation of proliferation and differentiation in epidermal keratinocytes, as well as in the survival, angiogenesis and metastasis of cancer cells. Cetuximab is a chimeric monoclonal antibody selective for the epidermal growth factor receptor that induces a broad range of cellular responses that enhance tumor sensitivity to radiotherapy and ...

Cetuximab-induced acneiform eruption and the response to isotretinoin.

Sorafenib-Associated Facial Acneiform Eruption

INTRODUCTION Sorafenib is an oral multikinase inhibitor that targets tumor cell angiogenesis and proliferation. Drug-associated cutaneous adverse events, such as alopecia and hand-foot skin reaction, occur frequently. Sorafenib-related side effects affecting hair, nails, and skin are summarized and the characteristics of sorafenib-treated patients who developed acneiform facial lesions are revi...